Literature DB >> 8990511

European Union Concerted Action on Risk Assessment in Lyme Borreliosis: clinical case definitions for Lyme borreliosis.

G Stanek1, S O'Connell, M Cimmino, E Aberer, W Kristoferitsch, M Granström, E Guy, J Gray.   

Abstract

The EU Concerted Action on Risk Assessment in Lyme Borreliosis (EUCALB) has consulted other clinicians and scientists in Europe to produce case definitions of the principal manifestations of European Lyme borreliosis. These case definitions will not only be helpful in supporting its own research interests, but are also intended to assist other clinicians in appropriate management and to support further studies aimed at determining the full clinical spectrum of the disease. The case definitions were achieved after a series of meetings organised by EUCALB with other expert clinicians and scientists from twelve European countries. The definitions and the diagnostic criteria presented thus represent the consensus reached at these meetings. The proposed case definitions consider skin, nervous system, cardiac and musculoskeletal presentations and the role of laboratory investigation in supporting diagnosis.

Entities:  

Mesh:

Year:  1996        PMID: 8990511

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  42 in total

1.  Validity of interpretation criteria for standardized Western blots (immunoblots) for serodiagnosis of Lyme borreliosis based on sera collected throughout Europe.

Authors:  U Hauser; G Lehnert; B Wilske
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

2.  A European multicenter study of immunoblotting in serodiagnosis of lyme borreliosis.

Authors:  J Robertson; E Guy; N Andrews; B Wilske; P Anda; M Granström; U Hauser; Y Moosmann; V Sambri; J Schellekens; G Stanek; J Gray
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Comparison of immunofluorescence assay (IFA) and LIAISON in patients with different clinical manifestations of Lyme borreliosis.

Authors:  Tjasa Cerar; Eva Ruzic-Sabljic; Joze Cimperman; Franc Strle
Journal:  Wien Klin Wochenschr       Date:  2006-11       Impact factor: 1.704

4.  Retrobulbar optic neuritis: a complication of Lyme disease?

Authors:  E Krim; D Guehl; P Burbaud; A Lagueny
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-12       Impact factor: 10.154

5.  Humoral immune responses in patients with Lyme neuroborreliosis.

Authors:  Tjasa Cerar; Katarina Ogrinc; Franc Strle; Eva Ruzić-Sabljić
Journal:  Clin Vaccine Immunol       Date:  2010-02-17

6.  Decreased up-regulation of the interleukin-12Rbeta2-chain and interferon-gamma secretion and increased number of forkhead box P3-expressing cells in patients with a history of chronic Lyme borreliosis compared with asymptomatic Borrelia-exposed individuals.

Authors:  S Jarefors; C K Janefjord; P Forsberg; M C Jenmalm; C Ekerfelt
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

7.  Relative frequency of Lyme borreliosis and of its clinical manifestations in Europe. European Community Concerted Action on Risk Assessment in Lyme Borreliosis.

Authors:  M A Cimmino
Journal:  Infection       Date:  1998 Sep-Oct       Impact factor: 3.553

8.  Cotton wool spots as possible indicators of retinal vascular pathology in ocular lyme borreliosis.

Authors:  Andres J Klaeger; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2008-10-15       Impact factor: 2.031

9.  Cytokines in Lyme borreliosis: lack of early tumour necrosis factor-alpha and transforming growth factor-beta1 responses are associated with chronic neuroborreliosis.

Authors:  Mona Widhe; Mattias Grusell; Christina Ekerfelt; Magnus Vrethem; Pia Forsberg; Jan Ernerudh
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

10.  CSF B--lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis.

Authors:  Unn Ljøstad; Ase Mygland
Journal:  J Neurol       Date:  2008-03-17       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.